LifeMD Forecast, price target & analysts
LifeMD Target price 2025 - Analyst rating & recommendation
LifeMD Classifications & Recommendation:
LifeMD Price Target
| Target Price | $11.72 |
| Price | $5.02 |
| Potential |
133.51%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target LifeMD 2026 .
The average LifeMD target price is $11.72.
This is
133.51%
register free of charge
$16.00
218.73%
register free of charge
$7.00
39.44%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend LifeMD to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the LifeMD stock has an average upside potential 2026 of
133.51%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 152.55 | 205.65 |
| 28.16% | 34.81% | |
| EBITDA Margin | -5.17% | 6.45% |
| 82.86% | 224.71% | |
| Net Margin | -19.19% | -11.24% |
| 65.21% | 41.41% |
9 Analysts have issued a sales forecast LifeMD 2024 . The average LifeMD sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an LifeMD EBITDA forecast 2024. The average LifeMD EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 LifeMD Analysts have issued a net profit forecast 2024. The average LifeMD net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.70 | -0.55 |
| 55.41% | 21.43% | |
| P/E | negative | |
| EV/Sales | 1.01 |
7 Analysts have issued a LifeMD forecast for earnings per share. The average LifeMD <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the LifeMD stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current LifeMD Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Keybanc | Locked ➜ Locked | Locked | Jan 08 2025 |
| Lake Street | Locked ➜ Locked | Locked | Dec 10 2024 |
| Mizuho | Locked ➜ Locked | Locked | Dec 04 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 11 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Sep 20 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Aug 20 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Keybanc: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Lake Street: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
Mizuho: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 11 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Sep 20 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Aug 20 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
